Devyser launches Genomic Blood Typing assay: All blood groups, one simple test
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
News | February 2, 2021
Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its efforts with the University Hospital of Zurich to further develop its unique NGS based test for early detection of kidney transplant recipients.
Through this project, Devyser aims to provide a certified CE-IVD kit, including reagents, protocols and software for data analysis ready to implement for routine use.
Link to the full press release:
Devyser receives EUR 750,000 Eurostars grant to develop novel DNA test for early detection of transplant rejection
